hormone therapy
Aging
Muscle Mass
Cognitive Health
Lab Testing
health
science
longevity
hormone therapy
Aging
Muscle Mass
Cognitive Health
Lab Testing
health
science
longevity
9 min read

Do Men Go Through Menopause? The Truth About Andropause

written by

Healthspan Team

published06 / 01 / 2026
Take Home Points

Andropause is real, but it's not the same as female menopause — it's a slow, decades-long hormonal decline, not a single event.

Testosterone drops roughly 1-2% per year after age 30. By your 60s, that adds up to a lot.

Symptoms like fatigue, brain fog, and belly fat have a hormonal signal worth measuring — not just chalking up to "aging."

The evidence for TRT is strongest in men with confirmed hypogonadism. It's not a fix-all for everyone in their 40s.

Enclomiphene is an option that stimulates your body's own testosterone without suppressing sperm production — important if fertility matters to you.

Clinical supervision isn't optional. Dosing, monitoring, and lab follow-up are what separate a protocol from a gamble.

Start with your labs. Your symptoms deserve data, not guesswork.

The Short Answer Is Yes. Sort Of.

You've seen the headlines. Middle-aged man gets tired, gains belly fat, loses his libido, and his doctor tells him it's just "getting older." Meanwhile, there's a whole clinical vocabulary, a stack of treatment options, and decades of research dedicated to the same hormonal shift when it happens in women. So what gives?

Do men go through menopause? Technically, no. But something real is happening — and it has a name. Andropause (also called late-onset hypogonadism, or sometimes just "male menopause") describes the gradual hormonal decline that most men will experience starting in their 30s and accelerating through their 40s and 50s. It's not a cliff edge like female menopause. It's more like a slow leak. And that's exactly why so many men miss it, or chalk it up to stress, bad sleep, or just aging poorly.

This article breaks down what's actually happening hormonally as men age, how it compares to female menopause, what symptoms are worth paying attention to, and what the evidence says about treatment. No hype, no scare tactics — just the science.

What Is Andropause, Really?

Andropause isn't a single event. It's a gradual hormonal transition driven primarily by declining testosterone, but also involving changes in other hormones including estradiol, DHEA, growth hormone, and cortisol. The term "male menopause" is a loose analogy, not a clinical match — but it captures something real.

Here's the core mechanism: testosterone production starts in the hypothalamus and pituitary gland, which signal the testes to produce testosterone via a feedback loop called the HPG axis (hypothalamic-pituitary-gonadal axis). Think of it like a thermostat system. As men age, the thermostat becomes less sensitive, the testes become less responsive, and the whole system produces less testosterone over time.

Testosterone levels in men peak in the late teens to mid-20s and begin declining at roughly 1-2% per year after age 30, according to large epidemiological studies. By age 70, many men have testosterone levels 30-50% lower than they did at their peak. That's not nothing.

But here's the catch: "low testosterone" isn't just a number. It's a combination of where your levels sit AND how sensitive your tissues are to the hormone you do have. Two men with the same lab value can feel completely different. This is why symptoms matter as much as bloodwork.

How Does Andropause Differ From Female Menopause?

Ready for the key distinction? Female menopause is abrupt, universal, and defined by a clear biological marker (the cessation of menstruation). Andropause is gradual, variable, and has no single clinical threshold that applies to every man. That difference has huge implications for how it's diagnosed and treated.

The timeline gap

Women typically experience menopause between ages 45 and 55, with estrogen dropping sharply over a few years. Men lose testosterone slowly over decades. A 45-year-old man might be well into andropause without any dramatic symptoms that would flag it in a standard doctor's visit.

The hormonal picture is more complex for men

Men produce estrogen too — primarily by converting testosterone into estradiol via an enzyme called aromatase. As total testosterone drops, so does estradiol. But if a man gains body fat (which contains aromatase), estradiol can actually rise relative to testosterone, throwing the ratio off. This is why "male menopause" isn't just about low T — it's about the whole hormonal ecosystem going out of balance.

The social recognition gap

Female menopause has dedicated clinical guidelines, a recognized specialty, and decades of public health conversation behind it. Andropause is still underdiscussed, underdiagnosed, and often dismissed. Men are significantly less likely to receive hormone testing at routine checkups. That's starting to change — but slowly.

Symptoms of Andropause: What to Actually Watch For

The symptom list for andropause overlaps frustratingly with "just getting older," which is part of why it gets missed. But there are patterns worth knowing.

  • Fatigue and low energy: Not just tired — a persistent, drag-through-the-day exhaustion that doesn't resolve with sleep.
  • Reduced libido: A noticeable, sustained drop in sexual desire, not a one-week slump.
  • Erectile dysfunction: Testosterone isn't the only factor in ED, but low T is a meaningful contributor.
  • Loss of muscle mass and strength: Testosterone is anabolic. When it drops, maintaining muscle becomes harder even with consistent training.
  • Increased body fat, especially visceral fat: The belly that appeared seemingly out of nowhere in your 40s? Hormonal shifts play a real role here.
  • Mood changes, irritability, and low motivation: Testosterone has direct effects on brain chemistry, dopamine signaling, and mood regulation.
  • Brain fog and difficulty concentrating: Cognitive symptoms are less discussed but well-documented in hypogonadal men.
  • Poor sleep quality: Low testosterone disrupts sleep architecture, and poor sleep suppresses testosterone. A feedback loop you don't want to be stuck in.
  • Reduced bone density: This one flies under the radar, but men lose bone mass as testosterone drops, increasing fracture risk over time.

None of these symptoms alone is diagnostic. But if several are present and progressively worsening, that's a signal worth investigating — not dismissing.

What the Evidence Actually Shows

Let's talk about what the research says, without overselling it.

Testosterone and cardiovascular health

Low testosterone in men is associated with increased cardiovascular risk, including higher rates of metabolic syndrome, type 2 diabetes, and coronary artery disease. A large meta-analysis found that men with low testosterone had a 35% higher risk of cardiovascular mortality compared to men with normal levels. Importantly, more recent data from the TRAVERSE trial — a randomized controlled trial of over 5,000 men — found that TRT did not increase major adverse cardiovascular events in men with hypogonadism, which had been a longstanding concern.

Testosterone and cognitive function

The brain is packed with androgen receptors. Low testosterone is associated with increased risk of cognitive decline and depression. Several studies have shown that TRT in hypogonadal men improves verbal memory, spatial ability, and mood scores. The effect sizes aren't enormous, but they're real. Note: most of this data comes from men with clinically low testosterone, not men at the low end of "normal." The benefit in men who are borderline is less clear.

Testosterone and body composition

This is where the evidence is strongest. Multiple randomized trials show that TRT in hypogonadal men increases lean mass, reduces fat mass, and improves insulin sensitivity. The Testosterone Trials (TTrials), a set of seven coordinated trials in men 65 and older with low testosterone, found significant improvements in sexual function, physical function, and mood — with modest but real improvements in bone density.

The reality check

Here's where intellectual honesty matters: TRT is not a fountain of youth. Most of the strongest benefits are seen in men with clinically confirmed hypogonadism, typically total testosterone below 300 ng/dL with symptoms. Men who are on the lower end of normal but not clinically deficient have less predictable responses. Optimizing testosterone won't reverse 20 years of poor lifestyle choices. And the long-term data, especially for younger men, is still accumulating. Promising, but not fully settled.

Who Is Andropause Treatment Actually Right For?

Not every man in his 40s needs TRT. But some men absolutely do, and are going undiagnosed and untreated for years. Here's how to think about whether you're in that group.

The ideal candidate for evaluation and potential treatment is typically a man over 35 with multiple andropause symptoms, confirmed low testosterone on at least two separate morning blood tests (morning because testosterone follows a diurnal rhythm and peaks in the morning), and no contraindications like active prostate cancer or untreated sleep apnea.

Men who might benefit from evaluation but not necessarily TRT include those with borderline testosterone, significant lifestyle factors (obesity, chronic stress, poor sleep) that could be driving hormonal suppression, or men who want to restore natural testosterone production rather than replace it. In that last case, Enclomiphene — a selective estrogen receptor modulator that stimulates the HPG axis — is an option worth discussing with a clinician. It can raise testosterone without suppressing the body's own production.

Risks and Side Effects of TRT: What You Need to Know

TRT is a real medical intervention with real considerations. Anyone telling you otherwise is selling something.

  • Fertility suppression: Exogenous testosterone suppresses sperm production. If you're considering having children, this is a serious conversation to have before starting TRT.
  • Erythrocytosis (elevated red blood cell count): TRT can increase hematocrit. This requires monitoring and occasional therapeutic phlebotomy (blood donation) to manage.
  • Testicular atrophy: The testes produce less testosterone when external supply comes in. Some protocols include HCG to mitigate this.
  • Estradiol conversion: Higher testosterone means more aromatase activity. If estradiol rises too high, it can cause symptoms like water retention and mood changes.
  • Skin reactions (with topical forms): Transfer to partners or children is a real risk with creams and gels. Application site and hygiene protocols matter.
  • Prostate health: TRT doesn't cause prostate cancer, but it can stimulate existing prostate tissue. Regular PSA monitoring is standard of care.

The answer to these risks isn't avoiding treatment if you need it — it's getting proper supervision, baseline labs, and regular follow-up monitoring. The risks are manageable when handled clinically.

How to Get Started: The Healthspan Approach to Male Hormones

If any of this sounds familiar — the fatigue, the brain fog, the body composition changes, the general sense that something is off — the right first step is data, not guesswork.

Healthspan's Complete Male Hormone Panel is designed exactly for this. It measures total and free testosterone, estradiol, LH, FSH, SHBG (sex hormone-binding globulin), thyroid function, and key metabolic markers — the full picture, not just a single testosterone number. You get context, not just a data point.

From there, if treatment is warranted, Healthspan offers multiple TRT pathways based on your labs, symptoms, and preferences. TRT Injection with Ongoing Care delivers testosterone cypionate via injection, typically weekly or biweekly, and is one of the most pharmacologically predictable delivery methods. TRT Cream with Ongoing Care offers a topical option for men who prefer to avoid injections. Both protocols include physician consultations, baseline and follow-up labs, dosing adjustments, and ongoing monitoring — not a prescription and a goodbye.

For men who want to stimulate their body's own testosterone production rather than replace it, Enclomiphene is available with clinical oversight. And for men who want a broader hormonal and longevity lens, Men's Hormone Health brings together hormonal optimization and long-term health strategy in one integrated protocol.

The next step is straightforward: get your labs done, talk to a clinician who takes this seriously, and make decisions based on your actual data.

Frequently Asked Questions About Male Menopause and Andropause

Do men go through menopause?

Not in the clinical sense. Female menopause is a defined biological event marked by the end of menstruation. Men experience a gradual, decades-long decline in testosterone and other hormones called andropause or late-onset hypogonadism. The symptoms overlap — fatigue, mood changes, reduced libido, body composition changes — but the timeline and hormonal pattern are different. It's real, it's measurable, and it's often undertreated.

At what age does andropause start?

Testosterone begins declining at roughly 1-2% per year starting around age 30. Noticeable symptoms typically emerge in the 40s or 50s, though some men notice changes earlier, especially if they have underlying health conditions, high stress, poor sleep, or excess body fat. There's no universal onset age — it's a spectrum, and individual variation is significant.

What are the most common symptoms of low testosterone in men?

The most commonly reported symptoms are fatigue, reduced libido, difficulty maintaining muscle mass, increased body fat (especially visceral fat), mood changes like irritability and low motivation, brain fog, and poor sleep quality. Reduced bone density is also common but often asymptomatic until a fracture occurs. Many of these overlap with general aging, which is why lab testing is essential for a proper diagnosis.

How is andropause diagnosed?

Andropause is typically diagnosed through a combination of symptoms and bloodwork. At minimum, this means measuring total testosterone (ideally on two separate morning draws, as levels vary throughout the day), free testosterone, LH, FSH, and SHBG. A complete hormone panel also looks at estradiol, thyroid function, and metabolic markers. A total testosterone below 300 ng/dL combined with symptoms is the generally accepted threshold for clinical hypogonadism.

Does testosterone replacement therapy actually work?

For men with confirmed low testosterone and symptoms, yes — the evidence is meaningful. The Testosterone Trials showed significant improvements in sexual function, physical function, mood, and bone density in older hypogonadal men. Benefits for body composition, including lean mass gain and fat reduction, are well-supported by multiple randomized controlled trials. The response is less predictable for men who are borderline or symptomatic but within normal lab ranges.

Is TRT safe long-term?

Recent data from the TRAVERSE trial — a large, randomized controlled trial of over 5,000 men — found no significant increase in major adverse cardiovascular events with TRT in hypogonadal men. Known risks include elevated red blood cell count (requiring monitoring), fertility suppression, and changes in estradiol. Proper clinical supervision, with regular labs and dosing adjustments, significantly reduces these risks. TRT is not without considerations, but managed correctly, it has a reasonable safety profile.

What's the difference between TRT and enclomiphene?

TRT replaces testosterone externally — you're supplying what your body isn't producing enough of. Enclomiphene stimulates your own HPG axis to produce more testosterone naturally, by blocking estrogen receptors in the hypothalamus and pituitary. The key difference: TRT suppresses your body's own production and sperm output, while enclomiphene preserves fertility and natural production. Enclomiphene is often preferred by younger men or those planning to have children.

Citations
  1. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metab. 2001;86(2):724-731. https://doi.org/10.1210/jcem.86.2.7219
  2. Shores MM, Matsumoto AM, Sloan KL, Kivlahan DR. Low serum testosterone and mortality in male veterans. Arch Intern Med. 2006;166(15):1660-1665. https://doi.org/10.1001/archinte.166.15.1660
  3. Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023;389(2):107-117. https://doi.org/10.1056/NEJMoa2215025
  4. Bhasin S, Ellenberg SS, Storer TW, et al. Effect of testosterone replacement on measures of mobility in older men with mobility limitation and low testosterone concentrations: secondary analyses of the Testosterone Trials. Lancet Diabetes Endocrinol. 2018;6(11):879-890. https://doi.org/10.1016/S2213-8587(18)30171-2
  5. Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of testosterone treatment in older men. N Engl J Med. 2016;374(7):611-624. https://doi.org/10.1056/NEJMoa1506119
  6. Moffat SD, Zonderman AB, Metter EJ, et al. Longitudinal assessment of serum free testosterone concentration predicts memory performance and cognitive status in elderly men. J Clin Endocrinol Metab. 2002;87(11):5001-5007. https://doi.org/10.1210/jc.2002-020419
  7. Corona G, Rastrelli G, Morelli A, Sarchielli E, Maggi M. Treatment of functional hypogonadism besides pharmacological substitution. World J Mens Health. 2020;38(3):256-270. https://doi.org/10.5534/wjmh.190061
  8. Wu FC, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363(2):123-135. https://doi.org/10.1056/NEJMoa0911101
  9. Tamhane UU, Shetty S, Doyle-Delgado K, et al. Testosterone and cardiovascular disease: a systematic review. Curr Atheroscler Rep. 2016;18(1):1. https://doi.org/10.1007/s11883-015-0554-2
  10. Ramasamy R, Scovell JM, Kovac JR, Lipshultz LI. Testosterone supplementation versus clomiphene citrate for hypogonadism: an age matched comparison of satisfaction and efficacy. J Urol. 2014;192(3):875-879. https://doi.org/10.1016/j.juro.2014.03.089